Back to Results

Teleflex Incorporated (TFX)

Teleflex Incorporated is a healthcare company that designs, develops, manufactures, and supplies single-use medical devices used in diagnostic and therapeutic procedures, with applications in critical care and surgery. Its portfolio spans vascular and emergency medicine products, including Arrow-branded catheters, intraosseous access systems, catheter navigation tools, and hemostatic products such as QuikClot. The company also provides interventional offerings, including coronary and peripheral devices, structural heart support products, closure systems, and related catheter-based technologies. In addition, Teleflex sells surgical products under brands such as Weck, MiniLap, Pleur-Evac, Deknatel, KMedic, Pilling, and Titan SGS. Its customers include hospitals, healthcare providers, and medical device manufacturers, and it also sells products online. Teleflex was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NYSE-TFX
$166.54
24.5% Upside
Undervalued
$147.70
10.4% Upside
Fair
Fair
—
—
1.36
1.0%
July 30, 2026
4,345.8x
1.9x
2.8x
5.934 B
8.307 B
31.6%
99.6%
3.9
-6.0%
16,694.6%
Send a message
Valuation • Fair Value

Teleflex Incorporated (NYSE-TFX) Fair Value by Valuation Model

Compare the primary fair value estimate for Teleflex Incorporated (NYSE-TFX) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$166.54

Estimated upside of 24.5% versus the current market price.

Fair Value Confidence

Med

Confidence level for the primary fair value estimate.

DCF Fair Value

$187.05

Discounted cash flow valuation reference.

Ben Graham Formula Value

$0.34

Classic Ben Graham valuation formula reference.

DDM Fair Value

$213.19

Dividend discount model valuation reference.

EPV Fair Value

$70.16

Earnings power value estimate.

Comps Fair Value

$154.33

Comparable-company valuation reference.

Analyst Price Target

$147.70

Analysts imply upside of 10.4%.

How to read these valuation models

Use this section to compare the primary fair value estimate for Teleflex Incorporated (NYSE-TFX) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Teleflex Incorporated (NYSE-TFX)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

2.127 B

Current operating scale indicator.

Revenue Forecast

2.289 B

Forward revenue estimate.

EBITDA

452.9 M

Current operating profitability reference.

EBITDA Forecast

492.9 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Teleflex Incorporated (NYSE-TFX) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Teleflex Incorporated (NYSE-TFX)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

5

Mid-range quality score.

Beneish M-Score

-2.75

No elevated caution signal from this screen.

Altman Z-Score

3.9

Relatively strong balance-sheet zone.

FCF / Net Income

16,694.6%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Teleflex Incorporated (NYSE-TFX). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Teleflex Incorporated (NYSE-TFX)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

July 30, 2026

Days to Earnings

9

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

1.0%

Income yield reference.

Upcoming Dividend

1.36

Upcoming distribution amount.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

USD

Currency used for the distribution.

Payout Ratio

-6.0%

Dividend payout reference.

How to read events and dividends

This section helps investors track time-sensitive items for Teleflex Incorporated (NYSE-TFX), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Teleflex Incorporated (NYSE-TFX) Stock Forecast & Technical Outlook

Review Teleflex Incorporated (NYSE-TFX) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Sell

The 15-minute technical read for Teleflex Incorporated (NYSE-TFX) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Teleflex Incorporated (NYSE-TFX) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Buy

The daily technical read for Teleflex Incorporated (NYSE-TFX) is currently Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Buy

The weekly technical read for Teleflex Incorporated (NYSE-TFX) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Neutral

The monthly technical read for Teleflex Incorporated (NYSE-TFX) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Teleflex Incorporated (NYSE-TFX)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Hold

Based on the available recommendation mix, Teleflex Incorporated (NYSE-TFX) has a Hold consensus, with 1 buy, 7 hold and 0 sell recommendations in the current data set.

Buy 1
Hold 7
Sell 0
FAQ • Fast Investor Answers

Teleflex Incorporated (NYSE-TFX) Stock FAQ

Quick answers about Teleflex Incorporated (NYSE-TFX) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$166.54
Estimated upside 24.5%
Valuation Rating
Undervalued
Estimated upside of 24.5%
Analyst Target
$147.70
Implied upside 10.4%
Financial Health
Fair
Current financial-health read

The current fair value estimate for Teleflex Incorporated (NYSE-TFX) is $166.54. This implies an estimated upside of 24.5% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 24.5% versus the current market price.

The available analyst price target for Teleflex Incorporated (NYSE-TFX) is $147.70. The analyst target implies estimated upside of 10.4%.

The current financial health read for Teleflex Incorporated (NYSE-TFX) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Teleflex Incorporated (NYSE-TFX) is July 30, 2026.

Based on the current data, dividend yield is 1.0%, upcoming dividend amount is 1.36.

The current P/E ratio listed for Teleflex Incorporated (NYSE-TFX) is 4,345.8x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Teleflex Incorporated is 5.934 B.

The current enterprise value listed for Teleflex Incorporated is 8.307 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Teleflex Incorporated is NYSE-TFX, and the stock is listed on NYSE.

Teleflex Incorporated (NYSE-TFX) is listed on NYSE.

The current debt-to-total-capital ratio listed for Teleflex Incorporated is 31.6%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Teleflex Incorporated is 99.6%. Free float helps investors understand how much of the share base is available for public trading.

Similar Healthcare Equipment & Supplies Stocks on NYSE View more

Abbott Laboratories (ABT) Abbott Laboratories (ABT)
Stryker Corporation (SYK) Stryker Corporation (SYK)
Medtronic PLC (MDT) Medtronic PLC (MDT)
Boston Scientific Corp (BSX) Boston Scientific Corp (BSX)
Edwards Lifesciences Corp (EW) Edwards Lifesciences Corp (EW)
Becton Dickinson and Co (BDX) Becton Dickinson and Co (BDX)
Alcon AG (ALC) Alcon AG (ALC)
ResMed Inc (RMD) ResMed Inc (RMD)
Koninklijke Philips NV ADR (PHG) Koninklijke Philips NV ADR (PHG)
STERIS plc (STE) STERIS plc (STE)
Zimmer Biomet Holdings Inc (ZBH) Zimmer Biomet Holdings Inc (ZBH)
Solventum Corp (SOLV) Solventum Corp (SOLV)
Smith & Nephew SNATS Inc (SNN) Smith & Nephew SNATS Inc (SNN)
Penumbra Inc (PEN) Penumbra Inc (PEN)
Baxter International Inc (BAX) Baxter International Inc (BAX)
Globus Medical (GMED) Globus Medical (GMED)
Glaukos Corp (GKOS) Glaukos Corp (GKOS)
Bausch + Lomb Corp (BLCO) Bausch + Lomb Corp (BLCO)
Envista Holdings Corp (NVST) Envista Holdings Corp (NVST)
Haemonetics Corporation (HAE) Haemonetics Corporation (HAE)
Integer Holdings Corp (ITGR) Integer Holdings Corp (ITGR)
Butterfly Network, Inc (BFLY) Butterfly Network, Inc (BFLY)
Enovis Corp (ENOV) Enovis Corp (ENOV)
Inspire Medical Systems Inc (INSP) Inspire Medical Systems Inc (INSP)